EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(0.52) per share which met the analyst consensus estimate. This is a 23.81 percent decrease over losses of $(0.42) per share from the same period last year. The company reported quarterly sales of $11.56 million which beat the analyst consensus estimate of $10.87 million by 6.39 percent. This is a 28.31 percent increase over sales of $9.01 million the same period last year.
FSD Pharma Signs Agreement With iNGENu CRO To Conduct A Clinical Study To Assess The Safety And Pharmacokinetics Of Multiple Ascending Doses Of Lucid-21-302 In Healthy Adults
FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting
